VICL
Vical Incorporated
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Vical Inc is engaged in research and development of biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.
Market Cap: 28.1 Million
Primary Exchange: NASDAQ Capital Market
Website: http://www.vical.com
Shares Outstanding: 19.7 Million
Float: 18.8 Million
Dividend: 0.0 (0.0%)
Beta: 2.271057
Sector: Healthcare
Industry: Biotechnology
Ethical Flags
Longest drawdown: 813 trading days
From: 2013-03-08 To: 2016-05-31
Lowest Point:
SHAREHOLDER ALERT: WeissLaw LLP Investigates Vical Incorporated Acquisition
via: PR Newswire at 2019-06-12 09:45:00:000
NEW YORK , June 12, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Vical Incorporated ("VICL" or the "Company") (NASDAQ: VICL) in connection with the proposed acquisition of the C… read more...
SHAREHOLDER ALERT: WeissLaw LLP Investigates Vical Incorporated Acquisition
via: PR Newswire at 2019-06-12 09:45:00:000
NEW YORK , June 12, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Vical Incorporated ("VICL" or the "Company") (NASDAQ: VICL) in connection with the proposed acquisition of the C… read more...
Rejecting The Vical-Brickell Reverse Merger Could Unlock 50% Upside
via: SeekingAlpha at 2019-06-12 05:09:44:000
Vical ( VICL ) is a failed biopharmaceutical company which discontinued operations in February 2019 to seek strategic alternatives. On June 3rd, Vical announced the proposed merger with Brickell Biotech which values Vical at $40m but the market did not respond favorably to the announcement a… read more...
Rejecting The Vical-Brickell Reverse Merger Could Unlock 50% Upside
via: SeekingAlpha at 2019-06-12 05:09:44:000
Vical ( VICL ) is a failed biopharmaceutical company which discontinued operations in February 2019 to seek strategic alternatives. On June 3rd, Vical announced the proposed merger with Brickell Biotech which values Vical at $40m but the market did not respond favorably to the announcement a… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|